Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Ryan F. Porter"'
Autor:
Mazyar Shadman, Ian W Flinn, Moshe Y Levy, Ryan F Porter, John M Burke, Syed F Zafar, Jamal Misleh, Edwin C Kingsley, Habte A Yimer, Benjamin Freeman, Subramanya S Rao, Arvind Chaudhry, Praveen K Tumula, Mitul D Gandhi, Sudhir Manda, Dih-Yih Chen, Kunthel By, Linlin Xu, Ye Liu, Rocco Crescenzo, Adam Idoine, Xiaoping Zhang, Aileen Cohen, Jane Huang, Jeff P Sharman
Publikováno v:
The Lancet. Haematology. 10(1)
We hypothesised that zanubrutinib, a highly selective next-generation Bruton tyrosine kinase (BTK) inhibitor, would be a safe and active treatment for patients intolerant of ibrutinib, acalabrutinib, or both. We aimed to assess whether zanubrutinib w
Publikováno v:
Journal of Clinical Oncology. 39:66-66
66 Background: Aim: To prospectively evaluate cost avoidance during routine conduct of cancer clinical trials in a community based integrated delivery network (IDN) consisting of a health services provider group, a health insurance plan and a hospita
Autor:
Syed F. Zafar, Troy H. Guthrie, Jennifer L. Cultrera, Mazyar Shadman, Habte A. Yimer, Moshe Yair Levy, Ian W. Flinn, Aileen Cohen, Jeff Porter Sharman, Jamal Misleh, Jane Huang, Shibao Feng, Benjamin Bruce Freeman, Dih-Yih Chen, Arvind Chaudhry, Ed Kingsley, John M. Burke, Subramanya S. Rao, Ryan F. Porter
Publikováno v:
Journal of Clinical Oncology. 39:e19506-e19506
e19506 Background: Many patients (pts) with B-cell malignancies require continuous treatment with Bruton tyrosine kinase inhibitors (BTKi). Adverse events (AEs) are a common reason for ibrutinib (ibr) or acalabrutinib (acala) discontinuation. Early d
Autor:
Kenneth A. Kesler, Rutuja Atale, Sunil Badve, Ryan F. Porter, Madison Conces, Jarret Glasscock, Bryan P. Schneider, Patrick J. Loehrer, Milan Radovich, Jeffrey P. Solzak, Jin Zhu, Bradley A. Hancock
Publikováno v:
British Journal of Cancer
Thymomas are one of the most rarely diagnosed malignancies. To better understand its biology and to identify therapeutic targets, we performed next-generation RNA sequencing. The RNA was sequenced from 13 thymic malignancies and 3 normal thymus gland
Autor:
Matthew Burns, John T. Salter, Olumide B. Gbolahan, E. Gabriella Chiorean, Patrick J. Loehrer, Constantin T. Yiannoutsos, Ryan F. Porter
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 13(12)
Introduction Thymoma and thymic carcinoma (TC) are neoplastic diseases with reported chemosensitivity to a broad range of agents. However, because of the rarity of these diseases, few prospective trials have been conducted in patients with advanced t
Autor:
Madison Conces, Kenneth A. Kesler, Bryan P. Schneider, Yaman Suleiman, Milan Radovich, Ryan F. Porter, Sunil Badve, Patrick J. Loehrer
Publikováno v:
Journal of Clinical Oncology. 30:7032-7032
7032 Background: Thymic malignancies are rare with ~500 cases in the US per year. Apart from standard chemotherapy, treatment options are limited. Further, the challenge of histologic subtyping of these tumors along with an inadequate understanding o
Autor:
Matthew Burns, Aaron John Spittler, Robert P. Nelson, Ryan F. Porter, Madison Conces, Bilal Karim Siddiqui, Bryan P. Schneider, Milan Radovich, Kristen L. Shirar, Luis Rojas, Patrick J. Loehrer, Yaman Suleiman, Sunil Badve
Publikováno v:
Journal of Clinical Oncology. 30:7107-7107
7107 Background: Thymoma and thymic carcinoma (TC) are rare tumors, but represent the most common neoplasms of the anterior mediastinum. The vast majority of TET present in early stages with little data existing on factors influencing survival in pat
Autor:
Madison Conces, Sunil Badve, Kristen L Shirar, Robert P. Nelson, Milan Radovich, Patrick J. Loehrer, Luis Rojas, Matthew Burns, Ryan F. Porter, Bryan P. Schneider, Kenneth A. Kesler, Aaron John Spittler, Yaman Suleiman
Publikováno v:
Journal of Clinical Oncology. 30:7108-7108
7108 Background: TET represent a heterogeneous collection of rare tumors, thymoma and thymic carcinoma (TC). Prognosis is often based on WHO histology and Masaoka Stage (MS) with small series often lacking long-term follow-up or advance stage disease